Welcome to IsraPharm - Contact us at +972 7337 468 45 (Office)

Contact Us

Office Address

Weizman 14 st., Tel Aviv, Israel

Phone Number

+972 7337 46845 (Office)

Email Address

[email protected]



Add to Wishlist
Add to Wishlist


Phesgo is the first oncology drug to be a ready-to-use, fixed-dose combination of two HER2-targeted monoclonal antibodies, pertuzumab and trastuzumab, administered by subcutaneous injection over approximately 5-8 minutes.

The drug contains the same antibodies as those found in intravenous dosage forms and is a fixed-dose combination. Indications for the fixed combination are similar to those of pertuzumab and include both early and metastatic HER2-positive breast cancer.

The drug is indicated for use in combination with chemotherapy:

as neoadjuvant therapy in adult patients with HER2-positive locally advanced, edematous-infiltrative or early breast cancer with a high risk of relapse;
as adjuvant therapy in adult patients with HER2-positive early breast cancer at high risk of recurrence.

Fesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent, unresectable breast cancer who have not received prior HER2-specific therapy or chemotherapy for metastatic disease.

Active substance: pertuzumab + trastuzumab

Prescription medicine

Storage temperature 2-8 degrees


Additional information


600 Mg, 1200 Mg